Calendar

Financial Releases

Date Title  
Toggle Summary AbbVie Reports First-Quarter 2019 Financial Results
- Reports First-Quarter Diluted EPS of $1.65 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 14.4 Percent - First-Quarter Net Revenues Were $7.828 Billion, an Increase of 0.4 Percent on an Operational Basis, Excluding a 1.7 Percent Unfavorable Impact From Foreign Exchange -
Toggle Summary AbbVie to Host First-Quarter 2019 Earnings Conference Call
NORTH CHICAGO, Ill. , April 3, 2019 /PRNewswire/ --  AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its first-quarter 2019 financial results on Thursday, April 25 before the market opens. AbbVie will host a live webcast of the earnings conference call at 8
Toggle Summary AbbVie to Present at the Barclays Global Healthcare Conference
NORTH CHICAGO, Ill. , March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 . Michael Severino , vice chairman and president, will present at 9:15 a.m.
Toggle Summary AbbVie to Present at the Cowen Health Care Conference
NORTH CHICAGO, Ill. , Feb. 28, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 39 th Annual Cowen Health Care Conference on Tuesday, March 12, 2019 . Richard A. Gonzalez , chairman and chief executive officer, will present at 7:00
Toggle Summary AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , Feb. 21, 2019 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) declared a quarterly cash dividend of $1.07 per share. The cash dividend is payable May 15, 2019 to stockholders of record at the close of business on April 15, 2019 .
Toggle Summary AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results
- Reports Full-Year Diluted EPS of $3.66 on a GAAP Basis; Adjusted Diluted EPS of $7.91 Reflects Growth of 41.3 Percent - Delivers Full-Year Net Revenues of $32.753 Billion on a GAAP Basis; Adjusted Net Revenues of $32.733 Billion Increased 15.2 Percent on an Operational Basis - Full-Year Global
Toggle Summary AbbVie to Host Fourth-Quarter and Full-Year 2018 Earnings Conference Call
NORTH CHICAGO, Ill. , Jan. 3, 2019 /PRNewswire/ --  AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its fourth-quarter and full-year 2018 financial results on Friday, January 25, 2019 before the market opens. AbbVie will host a live webcast of the earnings
Toggle Summary AbbVie to Present at the 37th Annual J.P. Morgan Healthcare Conference
NORTH CHICAGO, Ill. , Dec. 20, 2018 /PRNewswire/ --  AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 37 th annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 . Michael Severino , M.D., Vice Chairman and President, will present at
Toggle Summary AbbVie Announces Executive Leadership Changes
NORTH CHICAGO, Ill. , Dec. 17, 2018 /PRNewswire/ --  AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced a new Executive Leadership Team structure designed to streamline its organizational structure and support its long-term growth strategy.  Effective
Toggle Summary AbbVie Announces $5 Billion Increase to Stock Repurchase Program
NORTH CHICAGO, Ill. , Dec. 13, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program. Purchases may be made from time to time at management's discretion.